GRAIL, LLC - Asset Resilience Ratio
GRAIL, LLC (GRAL) has an Asset Resilience Ratio of 28.34% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GRAL current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how GRAIL, LLC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of GRAIL, LLC.
Liquid Assets Composition Over Time
This chart breaks down GRAIL, LLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore GRAIL, LLC long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $805.96 Million | 28.34% |
| Total Liquid Assets | $805.96 Million | 28.34% |
Asset Resilience Insights
- Very High Liquidity: GRAIL, LLC maintains exceptional liquid asset reserves at 28.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
GRAIL, LLC Industry Peers by Asset Resilience Ratio
Compare GRAIL, LLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
LONZA GROUP UNSP.ADR 1/10
F:LO3A |
Diagnostics & Research | 3.04% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 13.42% |
|
Gencurix Inc
KQ:229000 |
Diagnostics & Research | 4.01% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for GRAIL, LLC (2018–2025)
The table below shows the annual Asset Resilience Ratio data for GRAIL, LLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.41% | $654.70 Million | $2.92 Billion | +4.00pp |
| 2024-12-31 | 18.41% | $549.24 Million | $2.98 Billion | -- |
| 2023-12-31 | 0.00% | $0.00 | $4.56 Billion | -- |
| 2020-12-31 | 58.51% | $413.29 Million | $706.30 Million | -4.61pp |
| 2019-12-31 | 63.12% | $401.15 Million | $635.52 Million | -16.41pp |
| 2018-12-31 | 79.53% | $546.26 Million | $686.85 Million | -- |
About GRAIL, LLC
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides deve… Read more